AstraZeneca AZN announced that the European Commission has approved its blockbuster cancer drug, Imfinzi (durvalumab), for a ...

Cambridge: AstraZeneca has received approval for Imfinzi (durvalumab) in the European Union (EU) for the treatment of adult ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...

British drugmaker AstraZeneca (LSE: AZN) has gained European approval for Imfinzi (durvalumab) in combination with ...

Drugmaker AstraZeneca said on Friday that its Imfinzi asset has been approved in the EU as the first and only perioperative ...

It comes amid reports that the drugs maker is considering moving its listing from the UK to the US in what would be a hammer ...

Imfinzi for stage III NSCLC that cannot be removed by surgery (PACIFIC study). On average, people who were treated with Imfinzi lived 16.8 months before their cancer got worse.

IMFINZI with IMJUDO and Platinum-Based Chemotherapy. Infusion-related reactions occurred in 2.9% (17/596) of patients receiving IMFINZI in combination with IMJUDO and platinum-based chemotherapy, ...

Imfinzi and Tecentriq are both drugs used to treat certain cancers. Learn how they’re similar and different to help you decide if one may be right for you.

The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Friday that Imfinzi (durvalumab) has been approved in the European Union for the treatment of adult patients with resectable ...